Sugi Predict

Sugi Predict / Compounds / SCHEMBL1001008

SCHEMBL1001008

SCHEMBL1001008

N#CCc1ccc(Br)cn1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.43
▸ MAPT P10636 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ GBA1 P04062 2/20 0.41
▸ CSNK2A1 P68400 2/20 0.39
▸ GRM2 Q14416 1/20 0.36
▸ KDM4E B2RXH2 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ ADRA2A P08913 2/20 0.33
▸ ADRA2B P18089 2/20 0.33
▸ ADRA2C P18825 2/20 0.33
▸ PLAU P00749 1/20 0.33
▸ MBOAT4 Q96T53 1/20 0.33
▸ BCAT2 O15382 1/20 0.32
▸ ATM Q13315 1/20 0.32
▸ L3MBTL1 Q9Y468 1/20 0.32
▸ PTGES O14684 1/20 0.31
▸ TSHR P16473 1/20 0.31
▸ NPC1 O15118 1/20 0.30
▸ PKM P14618 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16750001 0.80 ATM (0.40) MEN1MAPTKMT2AGBA1CSNK2A1
SCHEMBL30570874 0.80 ATM (0.40) MEN1MAPTKMT2AGBA1CSNK2A1
SCHEMBL3673652 0.77 KMT2A (0.44) MEN1MAPTKMT2AKDM4EATM
SCHEMBL30117237 0.77 KMT2A (0.44) MEN1MAPTKMT2AKDM4EATM
SCHEMBL4764338 0.76 GBA1 (0.39) MAPTKMT2AGBA1GRM2KDM4E
SCHEMBL23171396 0.75 MEN1 (0.43) MEN1MAPTKMT2AKDM4EALDH1A1
SCHEMBL1626810 0.75 MEN1 (0.43) MEN1MAPTKMT2AKDM4EALDH1A1
SCHEMBL28527924 0.75 ESR2 (0.44) MEN1MAPTKMT2AATML3MBTL1
SCHEMBL1762618 0.75 MEN1 (0.43) MEN1MAPTKMT2AADRA2AADRA2B
SCHEMBL702765 0.75 MAPT (0.43) MEN1MAPTKMT2AKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 192 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12527779-B2 Prostaglandin E2 (PGE2) EP4 receptor antagonists DOMAIN THERAPEUTICS (FR) 2026-01-20 — — US disclosed
WO-2025151728-A1 LIGAND DIRECTED DEGRADER OF IRAK4 BRISTOL-MYERS SQUIBB COMPANY (US) 2025-07-17 — — WO disclosed
EP-4558495-A1 HETEROARYL COMPOUNDS AS LIGAND DIRECTED DEGRADERS OF IRAK4 Bristol-Myers Squibb Company (US) 2025-05-28 — — EP disclosed
US-20250136592-A1 C-LINKED INHIBITORS OF ENL/AF9 YEATS BRIDGE MEDICINES 2025-05-01 — — US disclosed
US-20250115613-A1 DIARYL COMPOUND AS TUBULIN/SRC DUAL TARGET INHIBITOR Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) 2025-04-10 — — US disclosed
US-20250109119-A1 AMPK AGONISTS AND METHODS OF USE THEREOF EVVIA THERAPEUTICS INC (US) 2025-04-03 — — US disclosed
CN-114945571-B Cyclic compounds and methods of use thereof 薛定谔公司 2025-02-25 — — CN disclosed
CN-119490449-A Hydroxamic acid compound containing N-benzyl-2- (5-phenylpyridin-2-yl) acetamide and preparation method and application thereof 沈阳药科大学 2025-02-21 — — CN disclosed
CN-113135896-B Methylpyrazole derivatives as RET inhibitors 正大天晴药业集团股份有限公司 2024-12-06 — — CN disclosed
EP-4469436-A1 AMPK AGONISTS AND METHODS OF USE THEREOF Evvia Therapeutics, Inc. (US) 2024-12-04 — — EP disclosed
EP-1560488-A4 ANTIBACTERIAL AGENTS SMITHKLINE BEECHAM CORP (US) 2006-08-02 — — EP disclosed
EP-1654259-A1 CYCLOPROPYL GROUP SUBSTITUTED OXAZOLIDINONE ANTIBIOTICS AND DERIVATIVES THEREOF Merck & Co., Inc. (US) 2006-05-10 — — EP disclosed
EP-1646629-A2 CYCLOPROPYL GROUP SUBSTITUTED OXAZOLIDINONE ANTIBIOTICS AND DERIVATIVES THEREOF Merck & Co., Inc. (US) 2006-04-19 — — EP disclosed
EP-1633363-A1 PYRIDINYL ACETONITRILES Applied Research Systems ARS Holding N.V. (AN) 2006-03-15 — — EP disclosed
EP-1560488-A2 ANTIBACTERIAL AGENTS SMITHKLINE BEECHAM CORPORATION (US) 2005-08-10 — — EP disclosed
US-20050038092-A1 Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereof MERCK SHARP & DOHME CORP. 2005-02-17 — — US disclosed
WO-2005005420-A1 CYCLOPROPYL GROUP SUBSTITUTED OYAZOLIDINONE ANTIBIOTICS AND DERIVATIVES THEREOF MERCK & CO., INC. (US) 2005-01-20 — — WO disclosed
WO-2005005398-A2 CYCLOPROPYL GROUP SUBSTITUTED OXAZOLIDINONE ANTIBIOTICS AND DERIVATIVES THEREOF MERCK & CO., INC. (US) 2005-01-20 — — WO disclosed
WO-2004098607-A1 PYRIDINYL ACETONITRILES APPLIED RESEARCH SYSTEMS ARS HOLDING N. V. (AN) 2004-11-18 — — WO disclosed
WO-2004041210-A2 ANTIBACTERIAL AGENTS SMITHKLINE BEECHAM CORPORATION (US) 2004-05-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12527779-B2 Prostaglandin E2 (PGE2) EP4 receptor antagonists PTGER1, PTGER4, PTGER3 MEN1 3795/4885MAPT 4848/4885KMT2A 3563/4885
US-20250115613-A1 DIARYL COMPOUND AS TUBULIN/SRC DUAL TARGET INHIBITOR SRC, DSTYK, TUBB1 MEN1 3913/4885MAPT 26/4885KMT2A 1736/4885
US-20050038092-A1 Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereof OXA1L, ALAD, COASY MEN1 4037/4885MAPT 3578/4885KMT2A 4582/4885
US-20250109119-A1 AMPK AGONISTS AND METHODS OF USE THEREOF PRKAG3, PRKAG1, PRKAG2 MEN1 4574/4885MAPT 2734/4885KMT2A 2472/4885
US-20250136592-A1 C-LINKED INHIBITORS OF ENL/AF9 YEATS MLLT3, MLLT1, YEATS2 MEN1 3043/4885MAPT 3236/4885KMT2A 53/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.